Central Vytorin exec leaves Merck post-merger; Russia starts antitrust probe at Novo;

@FiercePharma: PhRMA not interested in free-sample limits. Report | Follow @FiercePharma

> Enrico P. Veltri, a Schering-Plough vice-president who played the central role in a controversial study of the cholesterol drug Vytorin, has left the company following its acquisition by Merck. Report

> Russia's antitrust regulator has launched an investigation into Novo Nordisk based on concerns that the drugmaker may be abusing its dominant position in the country by refusing to sign contracts with certain customers. News

> An unnamed drugmaker has applied for U.S. regulatory approval to sell a generic version of Allergan's eyelash-enhancing drug Latisse before its patent protection expires. Article

> Merck's China unit started work on a new manufacturing site in Hangzhou on Monday as part of its expansion plans for the country. Article

> Screening people for Alzheimer's disease and treating them early would add a year to the time they spend in less-severe stages of the malady, a Bristol-Myers Squibb study found. Report

> Sanofi Aventis' Egypt unit has launched a training program for 400 pharmacy students from all over the country. Story

> Johnson & Johnson subsidiary Janssen Pharmaceutica has selected Ceva Logistics to manage its European distribution centre. News

Biotech News

 @FierceBiotech: Biotech start-up wins Google's attention--and money. Report | Follow @FierceBiotech

 @JohnCFierce: Market votes on Vivus, up 31 pecent. Risks are present, but evidently manageable in Qnexa. Pregnancy concerns rate fairly high. | Follow @JohnCFierce

> Report: Steve Kaldor exits Ambrx CEO post. Report

> Eli Lilly bets big on late-stage Alzheimer's drugs. Story

> Vivus shares rally after FDA staffers detail Qnexa concerns. News

Manufacturing News

> Genzyme re-ups and beefs up business with Hospira for fill/finish ops. Report

> Pfizer levels playing field with counterfeiters. Item

> Merck's Nigeria test shows off anti-counterfeiting tech. Story

> Latest Tylenol recall hints at rolling recalls. Piece

Research News

> Researchers ready human trial of osteoarthritis stem cell therapy. News

>  Investigator takes a new approach on Alzheimer's. Article

> Sanger spinoff nabs $30M to develop better antibodies. Report

> Compound enhances neuron production. Story

> Second-gen take on Acomplia significantly trims body weight. Article

And inally... Cancer experts issued new guidelines on the use of preventive aromatase inhibitors such as Arimidex and Teslac. Report

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.